STCUBE
Develops immuno-oncology therapies targeting novel immune checkpoints for cancer.
052020 | KO
Overview
Corporate Details
- ISIN(s):
- KR7052020005
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 강남구 영동대로 511 2201(삼성동, 무역센터 트레이드타워), 강남구
- Website:
- https://www.stcube.com/en/
Description
STCube is a biopharmaceutical company specializing in the research and development of innovative immuno-oncology therapies. The company focuses on discovering treatments that target novel immune checkpoints to overcome cancer's immune evasion mechanisms. Its primary area of research involves BTN1A1, a novel immune checkpoint target often expressed in a mutually exclusive manner with PD-L1. STCube's lead drug candidate, Nelmastobart, is a first-in-class anti-BTN1A1 immune checkpoint inhibitor. This therapy is being developed to provide a new treatment option for patients with treatment-resistant, refractory, or recurrent cancers that have limited therapeutic alternatives. The company utilizes a precision-medicine, biomarker-driven approach in its clinical development programs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-04-26 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 22.3 KB | ||
| 2022-04-26 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 22.3 KB | ||
| 2022-04-26 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.5 KB | ||
| 2022-04-25 00:00 |
기업설명회(IR)개최
|
Korean | 6.9 KB | ||
| 2022-04-06 00:00 |
[기재정정]주요사항보고서(유상증자결정)
|
Korean | 30.3 KB | ||
| 2022-04-06 00:00 |
투자설명서
|
Korean | 2.4 MB | ||
| 2022-04-06 00:00 |
[발행조건확정]증권신고서(지분증권)
|
Korean | 118.1 KB | ||
| 2022-04-06 00:00 |
유상증자1차발행가액결정
|
Korean | 7.7 KB | ||
| 2022-04-06 00:00 |
권리락(유상증자)
|
Korean | 3.5 KB | ||
| 2022-03-30 00:00 |
[기재정정]증권신고서(지분증권) (2022.05)
|
Korean | 2.8 MB | ||
| 2022-03-24 00:00 |
정기주주총회결과
|
Korean | 29.7 KB | ||
| 2022-03-24 00:00 |
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 9.6 KB | ||
| 2022-03-22 00:00 |
[기재정정]증권신고서(지분증권) (2022.05)
|
Korean | 2.9 MB | ||
| 2022-03-16 00:00 |
투자판단관련주요경영사항(면역항암제 hSTC810의 식품의약품안전처 임상 1상 시험계획 승인)
|
Korean | 14.1 KB | ||
| 2022-03-07 00:00 |
주요사항보고서(유상증자결정)
|
Korean | 26.7 KB |
Automate Your Workflow. Get a real-time feed of all STCUBE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for STCUBE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for STCUBE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
